Ranking Year:
# | Company Name | Region | Tech Topics | Total |
|---|
1 | Patent: 4 | |||
2 | Patent: 4 | |||
3 | Patent: 4 | |||
4 | Patent: 4 | |||
5 | Patent: 3 |
Top 5 Key Players companies in Voglibose
by Most Patent Filings in the Japan in 2022
The Voglibose top 5 is Discovery PatSnap’ annual ranking of the top 5 Most Patent Filings Voglibose Key Players in the Japan. Discovery has identified the top key players, startups & unicorns, fast-growings, news entrants in 2022, ranking from differnt perspectives, including patent filing intensity, academic research capability, news media heat. The company list is generated from various data types.
Voglibose (INN and USAN, trade name Voglib, marketed by Mascot Health Series) is an alpha-glucosidase inhibitor used for lowering post-prandial blood glucose levels in people with diabetes mellitus. Voglibose delays the absorption of glucose thereby reducing the risk of macrovascular complications. Voglibose is a research product of Takeda Pharmaceutical Company, Japan's largest pharmaceutical company. Voglibose was first launched in 1994, under the trade name BASEN, to improve postprandial hyperglycemia in diabetes mellitus.
Page generation time:
Aug 13 2025